Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Semin Oncol. 2010 Oct;37(5):473–484. doi: 10.1053/j.seminoncol.2010.09.001

Figure 2. Grade III/IV irAEs correlated with clinical response or clinical benefit.

Figure 2

The five studies evaluated each independently demonstrate a correlation between irAEs and either clinical response (CR+PR) (Attia 2005, Maker 2005, Downey 2007) or clinical benefit (CR+PR+SD) (Weber 2009 and Ku 2010). Several of the studies combined ipilimumab treatment with a second therapy (Attia 2005, Maker 2005, Downey 2007), limiting direct comparison. In Weber 2009, patients were treated with ipilimumab combined with a placebo or with budesonide; only the patients treated with ipilimumab monotherapy are analyzed here.